PCTIR_PSEAI
ID PCTIR_PSEAI Reviewed; 308 AA.
AC P0DV41;
DT 25-MAY-2022, integrated into UniProtKB/Swiss-Prot.
DT 25-MAY-2022, sequence version 1.
DT 03-AUG-2022, entry version 2.
DE RecName: Full=Pycsar effector protein PaPycTIR;
DE Short=PaPycTIR {ECO:0000303|PubMed:34644530};
DE EC=3.2.2.5 {ECO:0000250|UniProtKB:A0A0J5WTU0, ECO:0000305|PubMed:34644530};
GN Name=pycTIR {ECO:0000303|PubMed:34644530}; ORFNames=Ga0130373_10434;
OS Pseudomonas aeruginosa.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Pseudomonadales;
OC Pseudomonadaceae; Pseudomonas.
OX NCBI_TaxID=287;
RN [1]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC STRAIN=RW93;
RA Weiser R.;
RL Submitted (MAR-2015) to the EMBL/GenBank/DDBJ databases.
RN [2]
RP PROBABLE FUNCTION, AND CLASSIFICATION.
RC STRAIN=RW93;
RX PubMed=34644530; DOI=10.1016/j.cell.2021.09.031;
RA Tal N., Morehouse B.R., Millman A., Stokar-Avihail A., Avraham C.,
RA Fedorenko T., Yirmiya E., Herbst E., Brandis A., Mehlman T.,
RA Oppenheimer-Shaanan Y., Keszei A.F.A., Shao S., Amitai G., Kranzusch P.J.,
RA Sorek R.;
RT "Cyclic CMP and cyclic UMP mediate bacterial immunity against phages.";
RL Cell 0:0-0(2021).
CC -!- FUNCTION: Pycsar (pyrimidine cyclase system for antiphage resistance)
CC provides immunity against bacteriophage. The pyrimidine cyclase (PycC)
CC synthesizes cyclic nucleotides in response to infection; these serve as
CC specific second messenger signals. The signals activate the adjacent
CC effector, leading to bacterial cell death and abortive phage infection.
CC A clade A Pycsar system. {ECO:0000305|PubMed:34644530}.
CC -!- FUNCTION: The effector gene of a two-gene Pycsar system. Expression of
CC this and adjacent uridylate cyclase PaPycC (AC P0DV40) probably confers
CC resistance to bacteriophage. The genes are probably only expressed in
CC response to bacteriophage infection. Probably only responds to cUMP
CC (produced by its cognate NTP cyclase), acts by depleting cellular
CC NAD(+) levels. {ECO:0000305|PubMed:34644530}.
CC -!- CATALYTIC ACTIVITY:
CC Reaction=H2O + NAD(+) = ADP-D-ribose + H(+) + nicotinamide;
CC Xref=Rhea:RHEA:16301, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC ChEBI:CHEBI:17154, ChEBI:CHEBI:57540, ChEBI:CHEBI:57967; EC=3.2.2.5;
CC Evidence={ECO:0000250|UniProtKB:A0A0J5WTU0,
CC ECO:0000305|PubMed:34644530};
CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000305}.
CC -!- DOMAIN: Has an N-terminal cyclic nucleotide-binding domain and a C-
CC terminal Toll/interleukin-1 receptor-like domain (TIR) that probably
CC has the NAD(+) hydrolase activity. {ECO:0000305|PubMed:34644530}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; CUYG01000043; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR GO; GO:0016787; F:hydrolase activity; IEA:UniProtKB-KW.
DR GO; GO:0000166; F:nucleotide binding; IEA:UniProtKB-KW.
DR GO; GO:0051607; P:defense response to virus; IEA:UniProtKB-KW.
DR CDD; cd00038; CAP_ED; 1.
DR Gene3D; 2.60.120.10; -; 1.
DR InterPro; IPR018490; cNMP-bd-like.
DR InterPro; IPR000595; cNMP-bd_dom.
DR InterPro; IPR014710; RmlC-like_jellyroll.
DR InterPro; IPR019302; TIR-like_dom.
DR Pfam; PF00027; cNMP_binding; 1.
DR Pfam; PF10137; TIR-like; 1.
DR SMART; SM00100; cNMP; 1.
DR SUPFAM; SSF51206; SSF51206; 1.
DR PROSITE; PS50042; CNMP_BINDING_3; 1.
PE 4: Predicted;
KW Antiviral defense; Cytoplasm; Hydrolase; Nucleotide-binding.
FT CHAIN 1..308
FT /note="Pycsar effector protein PaPycTIR"
FT /id="PRO_0000455237"
FT REGION 160..278
FT /note="TIR-like"
FT /evidence="ECO:0000305|PubMed:34644530"
FT BINDING 54..143
FT /ligand="a nucleoside 3',5'-cyclic phosphate"
FT /ligand_id="ChEBI:CHEBI:58464"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00060"
SQ SEQUENCE 308 AA; 34233 MW; 39BD9D50D1B8341D CRC64;
MTTGKLIDRF EGPSGRAVLE EVLLEQKLVL GNQDLARRLA EVGTLEEIAK DAVLITEDAE
DSEVYFIITG HFQVKVHDRE VATRGGGDHV GEMAALVPTA KRSATVLATE PSIVLKVSAA
DFKSIADAYP SVWRQVTRQL VDRLHQRNDM VLPAHQSSHV FIICSVEALP IARAIENNLE
HDKFFVKTWT QGVFRASQYA LESLEEQLDE CDFAIAIAQP DDSVTMREET KNTPRDNVIF
ELGLFVGRLG RARTFLLEPR GDEVHLPSDL KGLTTIGYRL TKSEDQLPSS LSPACNQLRT
IFNKLGPK